Aug 18, 2026
Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O’Regan, moderated by Dr McArthur, including the following topics:
· Introduction (0:00)
· Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)
· Practical Considerations with Oral SERDs (15:43)
· Potential Role of Combination Approaches with Oral SERDs (26:33)
· Gastrointestinal Adverse Events Documented with Oral SERDs (38:19)
· Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:54)
· Other Class-Effect Toxicities Associated with Oral SERDs (1:00:56)
· Emerging Utility of Adjuvant Oral SERDs (1:10:20)
· Unique Toxicities Associated with 1 or More Oral SERDs (1:19:22)